BPG is committed to discovery and dissemination of knowledge
Cited by in CrossRef
For: Razok A, Ata F, Ahmed SMI, Al Mohanadi DHSH. Sodium-glucose co-transporter 2 inhibitors induced euglycemic diabetic ketoacidosis within four days of initiation. World J Diabetes 2022; 13(3): 272-274 [PMID: 35432760 DOI: 10.4239/wjd.v13.i3.272]
URL: https://www.wjgnet.com/1948-9358/full/v13/i3/272.htm
Number Citing Articles
1
Yiwei Huang, Xinyuan Yu, Changxin Li. Sodium–Glucose Cotransporter 2 Inhibitors: An Emerging Therapeutic Approach for Ischemic Stroke ManagementCNS Drugs 2025; 39(12): 1273 doi: 10.1007/s40263-025-01230-3
2
Nenad Lakušić, Ivana Sopek Merkaš, Ana Marija Slišković, Dora Cerovec. Euglycemic diabetic ketoacidosis: A rare but serious side effect of sodium-glucose co-transporter 2 inhibitorsWorld Journal of Cardiology 2022; 14(10): 561-564 doi: 10.4330/wjc.v14.i10.561
3
EmpagliflozinReactions Weekly 2022; 1912(1): 204 doi: 10.1007/s40278-022-17907-0